International Medical Case Reports Journal (Oct 2021)
Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
Abstract
Alexa Thibodeau, Nambi Nallasamy Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence: Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USATel +1 734 763 5506Fax +1 734 936 2340Email [email protected]: Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent.Keywords: anterior subcapsular cataract, enfortumab vedotin, urothelial carcinoma
